+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Biguanides Market by Type, Drug Class, Dosage Form, Formulation, Distribution Channel - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 199 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 6015114
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Biguanides Market grew from USD 5.24 billion in 2023 to USD 5.51 billion in 2024. It is expected to continue growing at a CAGR of 5.37%, reaching USD 7.57 billion by 2030.

Biguanides, a class of oral antihyperglycemic drugs, are primarily used to manage type 2 diabetes by decreasing glucose production in the liver and improving insulin sensitivity. Metformin is the most well-known biguanide, often used as a first-line treatment due to its efficacy, safety profile, and limited side effects. The necessity and application of biguanides are chiefly driven by the rising prevalence of type 2 diabetes, an increasingly sedentary lifestyle, and escalating obesity rates. Beyond diabetes management, applications extend to polycystic ovary syndrome (PCOS) treatments and emerging cancer research due to metformin's potential antitumor effects. The end-use scope predominantly includes pharmaceutical companies, hospitals, and healthcare providers. Key growth drivers in the biguanides market include increasing diabetes prevalence, expanded clinical applications, and ongoing research into novel therapeutic uses. Potential opportunities lie in the development of extended-release formulations to enhance patient adherence, as well as exploration into biguanide derivatives targeting non-diabetic conditions. Companies could capitalize on partnerships with research institutions to further therapeutic applications, ensuring alignment with emerging regulatory trends to streamline market entry. However, market growth is constrained by limitations such as the risk of lactic acidosis, particularly in people with renal impairments, and competition from newer antidiabetic medications, such as SGLT2 inhibitors and GLP-1 receptor agonists. Innovation opportunities are abundant in integrating biguanides with digital health solutions for personalized diabetes management, development of novel drug delivery systems, and expanding usage in combination therapies to address resistance issues. The market remains competitive yet promising with opportunities for R&D investments tailored towards versatile applications beyond conventional diabetes management. The overall nature of the market conveys a dynamic landscape highly influenced by clinical advancements, regulatory frameworks, and shifting patient demographics, all underscoring the importance of strategic foresight in navigating emerging market trends effectively.

Understanding Market Dynamics in the Biguanides Market

The Biguanides Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Increasing prevalence of type 2 diabetes driving demand for effective treatment options like biguanides
    • Rising healthcare expenditure and government initiatives boosting awareness and accessibility of diabetes medications
    • Technological advancements in pharmaceutical formulations improving efficacy and patient compliance of biguanides
    • Growing geriatric population more susceptible to diabetes and related comorbidities necessitating targeted treatments
  • Market Restraints
    • Potential side effects of Biguanides limiting patient adherence
    • High costs associated with research, development, and commercialization of Biguanides
  • Market Opportunities
    • Advancements in biguanides research and development focused on novel delivery mechanisms and formulations
    • Growing popularity of natural and plant-based biguanides in dietary supplements and nutraceuticals
    • Opportunities in emerging markets with increasing healthcare spending and awareness of lifestyle diseases
  • Market Challenges
    • The effect of emerging alternatives on the demand for biguanides in pharmaceutical applications
    • Environmental and health concerns associated with long-term use of biguanides in industries

Exploring Porter’s Five Forces for the Biguanides Market

Porter’s Five Forces framework further strengthens the insights of the Biguanides Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Biguanides Market

External macro-environmental factors deeply influence the performance of the Biguanides Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Biguanides Market

The Biguanides Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Biguanides Market

The Biguanides Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Biguanides Market

The Biguanides Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Biguanides Market, highlighting leading vendors and their innovative profiles. These include Amneal Pharmaceuticals, Inc., AstraZeneca PLC, Aurobindo Pharma Limited, Bayer AG, Biocon Limited, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Cipla Limited, Dr. Reddy's Laboratories Ltd., Eli Lilly and Co Ltd., Endo International PLC, GlaxoSmithKline PLC, Glenmark Pharmaceuticals Ltd., Hikma Pharmaceuticals PLC, Lupin Pharmaceuticals, Inc., Mallinckrodt Pharmaceuticals, Merck & Co., Inc., Mylan N.V., Novartis AG, Pfizer Inc., Player Name, Sanofi S.A., Servier Laboratories, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Wockhardt Ltd., and Zydus Lifesciences Ltd..

Market Segmentation & Coverage

This research report categorizes the Biguanides Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Type
    • Finformin
    • Metformin
  • Drug Class
    • Branded
    • Generic
  • Dosage Form
    • Oral Solutions
    • Tablets
  • Formulation
    • Extended-release
    • Immediate-release
  • Distribution Channel
    • Offline
    • Online
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of type 2 diabetes driving demand for effective treatment options like biguanides
5.1.1.2. Rising healthcare expenditure and government initiatives boosting awareness and accessibility of diabetes medications
5.1.1.3. Technological advancements in pharmaceutical formulations improving efficacy and patient compliance of biguanides
5.1.1.4. Growing geriatric population more susceptible to diabetes and related comorbidities necessitating targeted treatments
5.1.2. Restraints
5.1.2.1. Potential side effects of Biguanides limiting patient adherence
5.1.2.2. High costs associated with research, development, and commercialization of Biguanides
5.1.3. Opportunities
5.1.3.1. Advancements in biguanides research and development focused on novel delivery mechanisms and formulations
5.1.3.2. Growing popularity of natural and plant-based biguanides in dietary supplements and nutraceuticals
5.1.3.3. Opportunities in emerging markets with increasing healthcare spending and awareness of lifestyle diseases
5.1.4. Challenges
5.1.4.1. The effect of emerging alternatives on the demand for biguanides in pharmaceutical applications
5.1.4.2. Environmental and health concerns associated with long-term use of biguanides in industries
5.2. Market Segmentation Analysis
5.2.1. Type: Wide use of metformin owing to its efficacy, better safety profile, and affordability
5.2.2. Distribution Channel: Increasing engagement on online platforms due to price comparison, subscription services for regular medication delivery, and purchasing discretion.
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Biguanides Market, by Type
6.1. Introduction
6.2. Finformin
6.3. Metformin
7. Biguanides Market, by Drug Class
7.1. Introduction
7.2. Branded
7.3. Generic
8. Biguanides Market, by Dosage Form
8.1. Introduction
8.2. Oral Solutions
8.3. Tablets
9. Biguanides Market, by Formulation
9.1. Introduction
9.2. Extended-release
9.3. Immediate-release
10. Biguanides Market, by Distribution Channel
10.1. Introduction
10.2. Offline
10.3. Online
11. Americas Biguanides Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Biguanides Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa Biguanides Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. Market Share Analysis, 2023
14.2. FPNV Positioning Matrix, 2023
14.3. Competitive Scenario Analysis
14.3.1. Zydus receives USFDA approval for Zituvimet XR tablets
14.3.2. Lupin acquires two diabetes brands from Boehringer Ingelheim
14.3.3. Xigduo XR approved in China for adults with type-2 diabetes
14.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. BIGUANIDES MARKET RESEARCH PROCESS
FIGURE 2. BIGUANIDES MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL BIGUANIDES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL BIGUANIDES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL BIGUANIDES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BIGUANIDES MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
FIGURE 7. GLOBAL BIGUANIDES MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
FIGURE 9. GLOBAL BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2023 VS 2030 (%)
FIGURE 11. GLOBAL BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL BIGUANIDES MARKET SIZE, BY FORMULATION, 2023 VS 2030 (%)
FIGURE 13. GLOBAL BIGUANIDES MARKET SIZE, BY FORMULATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 15. GLOBAL BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. AMERICAS BIGUANIDES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. AMERICAS BIGUANIDES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. UNITED STATES BIGUANIDES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 19. UNITED STATES BIGUANIDES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. ASIA-PACIFIC BIGUANIDES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 21. ASIA-PACIFIC BIGUANIDES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA BIGUANIDES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA BIGUANIDES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 24. BIGUANIDES MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 25. BIGUANIDES MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. BIGUANIDES MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL BIGUANIDES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BIGUANIDES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BIGUANIDES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. BIGUANIDES MARKET DYNAMICS
TABLE 7. GLOBAL BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BIGUANIDES MARKET SIZE, BY FINFORMIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BIGUANIDES MARKET SIZE, BY METFORMIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BIGUANIDES MARKET SIZE, BY BRANDED, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BIGUANIDES MARKET SIZE, BY GENERIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BIGUANIDES MARKET SIZE, BY ORAL SOLUTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BIGUANIDES MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BIGUANIDES MARKET SIZE, BY EXTENDED-RELEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BIGUANIDES MARKET SIZE, BY IMMEDIATE-RELEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BIGUANIDES MARKET SIZE, BY OFFLINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BIGUANIDES MARKET SIZE, BY ONLINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. AMERICAS BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 23. AMERICAS BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 24. AMERICAS BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 25. AMERICAS BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 26. AMERICAS BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 27. AMERICAS BIGUANIDES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 28. ARGENTINA BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 29. ARGENTINA BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 30. ARGENTINA BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 31. ARGENTINA BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 32. ARGENTINA BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 33. BRAZIL BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 34. BRAZIL BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 35. BRAZIL BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 36. BRAZIL BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 37. BRAZIL BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 38. CANADA BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 39. CANADA BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 40. CANADA BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 41. CANADA BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 42. CANADA BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 43. MEXICO BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 44. MEXICO BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 45. MEXICO BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 46. MEXICO BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 47. MEXICO BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES BIGUANIDES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 54. ASIA-PACIFIC BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 55. ASIA-PACIFIC BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 56. ASIA-PACIFIC BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 57. ASIA-PACIFIC BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 58. ASIA-PACIFIC BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 59. ASIA-PACIFIC BIGUANIDES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 60. AUSTRALIA BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 61. AUSTRALIA BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 62. AUSTRALIA BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 63. AUSTRALIA BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 64. AUSTRALIA BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 65. CHINA BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 66. CHINA BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 67. CHINA BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 68. CHINA BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 69. CHINA BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 70. INDIA BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 71. INDIA BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 72. INDIA BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 73. INDIA BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 74. INDIA BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 75. INDONESIA BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 76. INDONESIA BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 77. INDONESIA BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 78. INDONESIA BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 79. INDONESIA BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 80. JAPAN BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 81. JAPAN BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 82. JAPAN BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 83. JAPAN BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 84. JAPAN BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 85. MALAYSIA BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 86. MALAYSIA BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 87. MALAYSIA BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 88. MALAYSIA BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 89. MALAYSIA BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 90. PHILIPPINES BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 91. PHILIPPINES BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 92. PHILIPPINES BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 93. PHILIPPINES BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 94. PHILIPPINES BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 95. SINGAPORE BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 96. SINGAPORE BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 97. SINGAPORE BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 98. SINGAPORE BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 99. SINGAPORE BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 100. SOUTH KOREA BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 101. SOUTH KOREA BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 102. SOUTH KOREA BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 103. SOUTH KOREA BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 104. SOUTH KOREA BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 105. TAIWAN BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 106. TAIWAN BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 107. TAIWAN BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 108. TAIWAN BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 109. TAIWAN BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 110. THAILAND BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 111. THAILAND BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 112. THAILAND BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 113. THAILAND BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 114. THAILAND BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 115. VIETNAM BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 116. VIETNAM BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 117. VIETNAM BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 118. VIETNAM BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 119. VIETNAM BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 120. EUROPE, MIDDLE EAST & AFRICA BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 121. EUROPE, MIDDLE EAST & AFRICA BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 122. EUROPE, MIDDLE EAST & AFRICA BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 123. EUROPE, MIDDLE EAST & AFRICA BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 124. EUROPE, MIDDLE EAST & AFRICA BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 125. EUROPE, MIDDLE EAST & AFRICA BIGUANIDES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 126. DENMARK BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 127. DENMARK BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 128. DENMARK BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 129. DENMARK BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 130. DENMARK BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 131. EGYPT BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 132. EGYPT BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 133. EGYPT BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 134. EGYPT BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 135. EGYPT BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 136. FINLAND BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 137. FINLAND BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 138. FINLAND BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 139. FINLAND BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 140. FINLAND BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 141. FRANCE BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 142. FRANCE BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 143. FRANCE BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 144. FRANCE BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 145. FRANCE BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 146. GERMANY BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 147. GERMANY BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 148. GERMANY BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 149. GERMANY BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 150. GERMANY BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 151. ISRAEL BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 152. ISRAEL BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 153. ISRAEL BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 154. ISRAEL BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 155. ISRAEL BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 156. ITALY BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 157. ITALY BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 158. ITALY BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 159. ITALY BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 160. ITALY BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 161. NETHERLANDS BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 162. NETHERLANDS BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 163. NETHERLANDS BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 164. NETHERLANDS BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 165. NETHERLANDS BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 166. NIGERIA BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 167. NIGERIA BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 168. NIGERIA BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 169. NIGERIA BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 170. NIGERIA BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 171. NORWAY BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 172. NORWAY BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 173. NORWAY BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 174. NORWAY BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 175. NORWAY BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 176. POLAND BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 177. POLAND BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 178. POLAND BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 179. POLAND BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 180. POLAND BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 181. QATAR BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 182. QATAR BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 183. QATAR BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 184. QATAR BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 185. QATAR BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 186. RUSSIA BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 187. RUSSIA BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 188. RUSSIA BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 189. RUSSIA BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 190. RUSSIA BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 191. SAUDI ARABIA BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 192. SAUDI ARABIA BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 193. SAUDI ARABIA BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 194. SAUDI ARABIA BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 195. SAUDI ARABIA BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 196. SOUTH AFRICA BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 197. SOUTH AFRICA BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 198. SOUTH AFRICA BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 199. SOUTH AFRICA BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 200. SOUTH AFRICA BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 201. SPAIN BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 202. SPAIN BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 203. SPAIN BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 204. SPAIN BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 205. SPAIN BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 206. SWEDEN BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 207. SWEDEN BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 208. SWEDEN BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 209. SWEDEN BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 210. SWEDEN BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 211. SWITZERLAND BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 212. SWITZERLAND BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 213. SWITZERLAND BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 214. SWITZERLAND BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 215. SWITZERLAND BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 216. TURKEY BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 217. TURKEY BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 218. TURKEY BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 219. TURKEY BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 220. TURKEY BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 221. UNITED ARAB EMIRATES BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 222. UNITED ARAB EMIRATES BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 223. UNITED ARAB EMIRATES BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 224. UNITED ARAB EMIRATES BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 225. UNITED ARAB EMIRATES BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 226. UNITED KINGDOM BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 227. UNITED KINGDOM BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 228. UNITED KINGDOM BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 229. UNITED KINGDOM BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 230. UNITED KINGDOM BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 231. BIGUANIDES MARKET SHARE, BY KEY PLAYER, 2023
TABLE 232. BIGUANIDES MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Biguanides Market, which are profiled in this report, include:
  • Amneal Pharmaceuticals, Inc.
  • AstraZeneca PLC
  • Aurobindo Pharma Limited
  • Bayer AG
  • Biocon Limited
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Co Ltd.
  • Endo International PLC
  • GlaxoSmithKline PLC
  • Glenmark Pharmaceuticals Ltd.
  • Hikma Pharmaceuticals PLC
  • Lupin Pharmaceuticals, Inc.
  • Mallinckrodt Pharmaceuticals
  • Merck & Co., Inc.
  • Mylan N.V.
  • Novartis AG
  • Pfizer Inc.
  • Player Name
  • Sanofi S.A.
  • Servier Laboratories
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Wockhardt Ltd.
  • Zydus Lifesciences Ltd.

Methodology

Loading
LOADING...

Table Information